{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:00:33Z","timestamp":1771578033074,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008332","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000}}],"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The tumor mutational burden (TMB) is increasingly recognized as an emerging biomarker that predicts improved outcomes or response to immune checkpoint inhibitors in cancer. A multitude of technical and biological factors make it difficult to compare TMB values across platforms, histologies, and treatments. Here, we present a mechanistic model that explains the association between panel size, histology, and TMB threshold with panel performance and survival outcome and demonstrate the limitations of existing methods utilized to harmonize TMB across platforms.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008332","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:49:54Z","timestamp":1604947794000},"page":"e1008332","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8981-0047","authenticated-orcid":true,"given":"Mahdi","family":"Golkaram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-2852","authenticated-orcid":true,"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Kruglyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shile","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-908X","authenticated-orcid":true,"given":"Sven","family":"Bilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"issue":"22","key":"pcbi.1008332.ref001","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"MD Hellmann","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pcbi.1008332.ref002","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"RM Samstein","year":"2019","journal-title":"Nature genetics"},{"issue":"1","key":"pcbi.1008332.ref003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"TA Chan","year":"2019","journal-title":"Annals of Oncology"},{"issue":"3","key":"pcbi.1008332.ref004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"JJ Havel","year":"2019","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"pcbi.1008332.ref005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.21037\/tlcr.2018.08.14","article-title":"Implementing tumor mutational burden (TMB) analysis in routine diagnostics\u2014a primer for molecular pathologists and clinicians","volume":"7","author":"M Allg\u00e4uer","year":"2018","journal-title":"Translational lung cancer research"},{"issue":"8","key":"pcbi.1008332.ref006","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"A Stenzinger","year":"2019","journal-title":"Genes, Chromosomes and Cancer"},{"issue":"6","key":"pcbi.1008332.ref007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.21037\/tlcr.2018.10.10","article-title":"Approach to evaluating tumor mutational burden in routine clinical practice","volume":"7","author":"J Truesdell","year":"2018","journal-title":"Translational lung cancer research"},{"issue":"4","key":"pcbi.1008332.ref008","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.31878","article-title":"Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"I Buchhalter","year":"2019","journal-title":"International Journal of Cancer"},{"key":"pcbi.1008332.ref009","volume-title":"Introduction to modern statistical mechanics","author":"D Chandler","year":"2009"},{"key":"pcbi.1008332.ref010","doi-asserted-by":"crossref","DOI":"10.1201\/9781439878132","volume-title":"Introduction to statistical physics","author":"K Huang","year":"2009"},{"key":"pcbi.1008332.ref011","volume-title":"The statistical mechanics of financial markets","author":"J Voit","year":"2005"},{"issue":"10","key":"pcbi.1008332.ref012","doi-asserted-by":"crossref","first-page":"104502","DOI":"10.1103\/PhysRevLett.110.104502","article-title":"Direct statistical simulation of out-of-equilibrium jets","volume":"110","author":"SM Tobias","year":"2013","journal-title":"Physical review letters"},{"key":"pcbi.1008332.ref013","unstructured":"Mehta P, Schwab DJ. An exact mapping between the variational renormalization group and deep learning. arXiv preprint arXiv:1410.3831. 2014 Oct 14."},{"issue":"1","key":"pcbi.1008332.ref014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"DM Merino","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"25","key":"pcbi.1008332.ref015","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"M Yarchoan","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"17","key":"pcbi.1008332.ref016","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","article-title":"Mutational landscape and sensitivity to immune checkpoint blockers","volume":"22","author":"RM Chabanon","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"pcbi.1008332.ref017","doi-asserted-by":"crossref","first-page":"v917","DOI":"10.1093\/annonc\/mdz394.078","article-title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407","volume":"30","author":"L Paz-Ares","year":"2019","journal-title":"Annals of Oncology"},{"issue":"6","key":"pcbi.1008332.ref018","doi-asserted-by":"crossref","first-page":"647","DOI":"10.21037\/tlcr.2018.09.22","article-title":"Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy","volume":"7","author":"LE Hendriks","year":"2018","journal-title":"Translational lung cancer research"},{"issue":"9","key":"pcbi.1008332.ref019","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels","volume":"144","author":"V Endris","year":"2019","journal-title":"International journal of cancer"},{"key":"pcbi.1008332.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00171","article-title":"Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non\u2013Small-Cell Lung Cancer","volume":"3","author":"NI Vokes","year":"2019","journal-title":"JCO precision oncology"},{"issue":"6230","key":"pcbi.1008332.ref021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"NA Rizvi","year":"2015","journal-title":"Science"},{"key":"pcbi.1008332.ref022","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"TN Schumacher","year":"2019","journal-title":"Annual review of immunology"},{"issue":"9","key":"pcbi.1008332.ref023","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"J Budczies","year":"2019","journal-title":"Annals of Oncology"},{"key":"pcbi.1008332.ref024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.01.019","article-title":"Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement","volume":"142","author":"J Budczies","year":"2020","journal-title":"Lung Cancer"},{"key":"pcbi.1008332.ref025","article-title":"TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted Sequencing","author":"C. Zhao","year":"2020","journal-title":"BioRxiv"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008332","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:12:47Z","timestamp":1697062367000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008332"}},"subtitle":[],"editor":[{"given":"Benjamin Muir","family":"Althouse","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008332","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1008332","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}